New molecular mechanisms of the unexpectedly complex role of VEGF in ulcerative colitis

Biochemical and Biophysical Research Communications

Volumn 399, Issue 4, 2010, Pages 613-616

  Tolstanova, Ganna ^a   Khomenko, Tetyana ^a   Deng, Xiaoming ^a   Szabo, Sandor ^a   Sandor, Zsuzsanna ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Akt; Erk1 2; Src; Ulcerative colitis; VEGF; VEGF receptor 2

Indexed keywords

INTERLEUKIN 10; IODOACETAMIDE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN TYROSINE KINASE; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; PROTEIN KINASE B; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL MEMBRANE PERMEABILITY; COLON; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; GENE INACTIVATION; MALE; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; ULCERATIVE COLITIS; WILD TYPE; ANIMAL; CAPILLARY PERMEABILITY; CHEMICALLY INDUCED; DRUG EFFECTS; GENETICS; KNOCKOUT MOUSE; METABOLISM; PHOSPHORYLATION; SPRAGUE DAWLEY RAT;

ANIMALS; CAPILLARY PERMEABILITY; COLITIS, ULCERATIVE; COLON; INTERLEUKIN-10; IODOACETAMIDE; MICE; MICE, KNOCKOUT; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

MUS; RATTUS;

EID: 77956266957     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.07.124     Document Type: Article

References (21)

1. Szabo S., Folkman J., Vattay P., et al. Duodenal ulcerogens: effect of FGF on cysteamine-induced duodenal ulcer. Mechanisms of Peptic Ulcer Healing 1991, 139-150. Kluwer Academic Publications, London. F. Halter, A. Garner, C.N.J. Tytgat (Eds.).
2. Szabo S., Sandor Z. Basic fibroblast growth factor and PDGF in GI diseases, Baillieres. Clin. Gastroenterol. 1996, 10:97-112.
3. Deng X., Szabo S., Khomenko T., et al. Gene therapy with adenoviral plasmids or naked DNA of vascular endothelial growth factor and platelet-derived growth factor accelerates healing of duodenal ulcer in rats. J. Pharmacol. Exp. Ther. 2004, 311:982-988.
4. Kojima T., Watanabe T., Hata K., Nagawa H. Basic fibroblast growth factor enema improves experimental colitis in rats. Hepatogastroenterology 2007, 54:1373-1377.
5. Thatch K.A., Mendelson K.G., Haber M.M., Schwartz M.Z. Growth factor manipulation of intestinal angiogenesis: a possible new paradigm in the management of inflammatory bowel disease. J. Surg. Res. 2009, 156:245-249.
6. Tolstanova G., Khomenko T., Deng X., et al. Neutralizing anti-vascular endothelial growth factor (VEGF) antibody reduces severity of experimental ulcerative colitis in rats: direct evidence for the pathogenic role of VEGF. J. Pharmacol. Exp. Ther. 2009, 328:749-757.
7. Dvorak H.F., Nagy J.A., Feng D., et al. Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. Curr. Top. Microbiol. Immunol. 1999, 237:97-132.
8. Scaldaferri F., Vetrano S., Sans M., et al. VEGF-A links angiogenesis and inflammation in inflammatory bowel disease pathogenesis. Gastroenterology 2009, 136:585-595.
9. Gille H., Kowalski J., Li B., et al. Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants. J. Biol. Chem. 2001, 276:3222-3230.
10. Rahimi N., Dayanir V., Lashkari K. Receptor chimeras indicate that the vascular endothelial growth factor receptor-1 (VEGFR-1) modulates mitogenic activity of VEGFR-2 in endothelial cells. J. Biol. Chem. 2000, 275:16986-16992.
11. Landgren E., Schiller P., Cao Y., et al. Placenta growth factor stimulates MAP kinase and mitogenicity but not phospholipase C-gamma and migration of endothelial cells expressing Flt 1. Oncogene 1998, 16:359-367.
12. Gavard J., Gutkind J.S. VEGF controls endothelial-cell permeability by promoting the β-arrestin-dependent endocytosis of VE-cadherin. Nat. Cell Biol. 2006, 8:1223-1234.
13. Kilic E., Kilic U., Wang Y., et al. The phosphatidylinositol-3 kinase/Akt pathway mediates VEGF's neuroprotective activity and induces blood brain barrier permeability after focal cerebral ischemia. FASEB. J. 2006, 20:1185-1187.
14. Gerber H.P., McMurtrey A., Kowalski J., et al. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J. Biol. Chem. 1998, 273:30336-30343.
15. Holmes K., Roberts O.L., Thomas A.M., Cross M.J. Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition. Cell Signal. 2007, 19:2003-2012.
16. Satoh H., Sato F., Takami K., Szabo S. New ulcerative colitis model induced by SH blockers in rats and the effects of antiinflammatory drugs on the colitis. Jpn. J. Pharmacol. 1997, 73:299-309.
17. + TH1-like responses. J. Clin. Invest. 1996, 98:1010-1020.
18. McLaren W.J., Anikijenko P., Thomas S.G., et al. In vivo detection of morphological and microvascular changes of the colon in association with colitis using fiberoptic confocal imaging (FOCI). Dig. Dis. Sci. 2002, 47:2424-2433.
19. Tolstanova G., Deng X.M., Khomenko T., et al. Endothelial damage and increased colonic vascular permeability precede epithelial "barrier" dysfunction in the development of experimental ulcerative colitis. Gastroenterology 2009, 136:A774.
20. Adenis A., Vanseymortier L., Foissey D., Colombel J.F., et al. Bevacizumab and postponed suture leakages after surgery for ulcerative colitis and rectal cancer. Gut 2007, 56:734.
21. Khalil P.N., Weiler V., Nelson P.J., et al. Nonmyeloablative stem cell therapy enhances microcirculation and tissue regeneration in murine inflammatory bowel disease. Gastroenterology 2007, 132:944-954.